Human Immunodeficiency Virus Clinical Trial
— HOLAHIVOfficial title:
Preventing Cardiometabolic Disease in HIV-Infected Latino Men Through a Culturally-Tailored Health Promotion Intervention
Verified date | July 2021 |
Source | University of Miami |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to examine the feasibility of an intervention to prevent chronic diseases like diabetes, high blood pressure, and obesity in midlife and older Latino adults living with HIV. The investigators expect that the participant will be in this study for seven months. Participants will be interviewed and asked to take part in walking groups.
Status | Completed |
Enrollment | 18 |
Est. completion date | October 27, 2020 |
Est. primary completion date | July 27, 2020 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - are Latino (self-identified); - are age 50+ years; - are male; - are HIV infected but are virologically suppressed (viral load <200 copies/mL); - volunteer informed consent; - have medical clearance by a physician; - expect to stay in Miami for the next 6 months; and - have documented risk of cardiometabolic disease. Exclusion Criteria: - diabetes diagnosis; - at baseline meet criteria for current major depressive disorder or generalized anxiety disorder; - meet criteria for current alcohol or other substance abuse disorders; - have a lifetime history of bipolar disorder or other psychotic disorder; - have a diagnosis of any neurodegenerative disorder or dementia (Parkinson's disease, Alzheimer's, vascular, frontotemporal dementia, etc.) or significant cognitive impairment as indicated by a Mini Mental Status Exam score <24; - have contraindications to physical activity outlined in the American College of Sports Medicine standards; - have high suicide risk i.e., intent or plan to attempt suicide in the near future (a response of "yes" to questions 3, 4, and/or 5 on the Paykel Questionnaire); - are unable to complete 10 m walk test; - currently residing in a nursing or group home; - have a terminal physical illness expected to result in the death within one year; - have an acute or severe medical illness that precludes them from safely participating in a health promotion intervention. |
Country | Name | City | State |
---|---|---|---|
United States | Jackson Memorial Mental Health Hospital | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Miami | National Institute on Minority Health and Health Disparities (NIMHD) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Eligible Participants Refusing to Participate. | Number of eligible participants refusing to participate. | Baseline | |
Primary | Retention Rate | Retention rate will be reported as the number of participants completing the post-intervention assessment. | Up to 3 months post intervention | |
Primary | Acceptability of Intervention | As measured by the total number of sessions attended by the participants as a whole. | Up to week 16 | |
Secondary | Change in Cardiometabolic Risk as Measured by Waist Circumference | As measured by the number of inches around the participant's waist. A waist circumference of 102 centimetres (40 inches) or more in men is associated with health problems such as type 2 diabetes, heart disease and high blood pressure. | Baseline, 7 months post intervention | |
Secondary | Change in Psychosocial Functioning as Measured by Depression Severity Scale | As measured by a 20-item Center for Epidemiologic Studies Depression (CES-D) scale. The possible range of scores are 0 to 60 with the higher scores indicating the presence of more symptomatology. | Baseline, Month 4, Month 7 | |
Secondary | Change in Health-related Quality of Life as Measured by the Short Form Health Survey (SF-12) | The SF-12v2 is a measure of health related quality of life and provides 2 scores 1) Mental Component Summary Score (MCS) and 2) Physical Component Summary Score (PCS). MCS scores range from 0 to 100, higher scores indicate better mental health related quality of life. | Baseline, Month 4, Month 7 | |
Secondary | Change in Psychosocial Functioning as Measured by the Patient Health Questionnaire (PHQ-9) | severity of depression will be measured by the 9-item PHQ-9. Scores range from 0 to 27. With scores of 1-4 indicating minimal depression and scores of 20-27 indicating severe depression. | Baseline, Month 4, Month 7 | |
Secondary | Change in Psychosocial Functioning as Measured by the Severity of Anxiety Using the Generalized Anxiety Disorder Scale | The 7-item Generalized Anxiety Disorder (GAD-7) scale will be used to measure the severity of anxiety. The scores range from 0 to 21 with scores of 0 to 5 indicating mild anxiety and scores of 15-21 indicating severe anxiety. | Baseline, Month 4, Month 7 | |
Secondary | Change in Psychosocial Functioning as Measured by the Severity of Anxiety Using the Perceived Stress Scale | The 14 item Healthy Families Program Perceived Stress Scale will be used to measure the severity of anxiety. PSS scores can range from 0 to 40 with higher scores indicated higher perception of stress. | Baseline, Month 4, Month 7 | |
Secondary | Change in Psychosocial Functioning as Measured by the Social Support Received | The 12 item Multidimensional Scale of Perceived Social support. After calculating the mean score across the categories a mean scale support score from 1 to 2.9 would indicate low support, whereas a mean score of 5.1 to 7 would indicate high support. | Baseline, Month 4, Month 7 | |
Secondary | Change in Lipid Profile as Measured by Total Cholesterol, HDL-C, LDL-C, Triglycerides | A total cholesterol value of less than 200 mg/dL (5.18 mmol/L) is desirable and 240 mg/dL (6.22 mmol/L) or higher is high. Average HDL-C level is 40-50 mg/dL (1.0-1.3 mmol/L) for men. Low HDL-C level, increased risk, is less than 40 mg/dL (1.0 mmol/L). Optimal LDL-C levels are less than 100 mg/d while high levels are 160-189 mg/dL (4.15-4.90 mmol/L). Desirable triglyceride levels are less than 150 mg/dL (1.70 mmol/L) while high levels are considered 200-499 mg/dL (2.3-5.6 mmol/L). | Baseline, Month 4, Month 7 | |
Secondary | Change in Hypertension as Measured by Systolic and Diastolic Blood Pressure. | Normal systolic and diastolic pressure is less than 120 mmHg and 80mmHg, respectively. High systolic and diastolic pressure is 140 mmHg or higher and 90 mmHg or higher, respectively. | Baseline, Month 4, Month 7 | |
Secondary | Change in Glucose as Measured by Glycated Hemoglobin (Hba1c) | The normal range for the hemoglobin A1c level is between 4% and 5.6%. Hemoglobin A1c levels between 5.7% and 6.4% mean a higher chance of getting diabetes. Levels of 6.5% or higher mean diabetes. | Baseline, Month 4, Month 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |